Roche and Ascletis announce collaboration to develop danoprevir in China
Cinnamon Girl said
Apr 16, 2013
Basel, Switzerland and Shanghai, China - 15 April 2013
Roche and Ascletis enter collaboration to advance treatment options for Chinese patients with Hepatitis C
Roche and Ascletis announced today that they have entered into a collaboration to develop and commercialize Roche`s investigational drug danoprevir in China for the treatment of Hepatitis-C Virus (HCV).
It is estimated that over 10 million patients in China are chronically infected with HCV. The majority of these are genotype 1b, which has proven highly responsive to danoprevir. Roche and Ascletis are joining forces to develop a therapy with the potential to address a serious public health problem and to provide an effective new treatment option for Chinese patients with HCV.
Danoprevir is an experimental HCV protease inhibitor.
Basel, Switzerland and Shanghai, China - 15 April 2013
Roche and Ascletis enter collaboration to advance treatment options for Chinese patients with Hepatitis C
Roche and Ascletis announced today that they have entered into a collaboration to develop and commercialize Roche`s investigational drug danoprevir in China for the treatment of Hepatitis-C Virus (HCV).
It is estimated that over 10 million patients in China are chronically infected with HCV. The majority of these are genotype 1b, which has proven highly responsive to danoprevir. Roche and Ascletis are joining forces to develop a therapy with the potential to address a serious public health problem and to provide an effective new treatment option for Chinese patients with HCV.
Danoprevir is an experimental HCV protease inhibitor.
Link to media release...
http://www.roche.com/media/media_releases/med-cor-2013-04-15.html